Microsoft Excel LibreOffice Calc

Long-term (Investment) Activity Analysis

Difficulty: Beginner


Ratios (Summary)

Eli Lilly & Co., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net fixed asset turnover 2.59 2.57 2.48 2.46 2.90
Total asset turnover 0.51 0.55 0.56 0.53 0.66
Equity turnover 1.97 1.52 1.37 1.28 1.31

Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017.

Net Fixed Asset Turnover

Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
Property and equipment, net 8,826,500  8,252,600  8,053,500  7,963,900  7,975,500 
Ratio
Net fixed asset turnover1 2.59 2.57 2.48 2.46 2.90
Benchmarks
Net Fixed Asset Turnover, Competitors
Abbott Laboratories 3.60 3.66 3.56 3.41 3.70
AbbVie Inc. 10.07 9.85 8.91 8.03 8.18
Allergan PLC 8.93 9.04 9.58 8.19 5.37
Amgen Inc. 4.37 4.41 4.27 3.70 3.40
Biogen Inc. 3.86 4.58 4.92 5.50 3.96
Bristol-Myers Squibb Co. 4.15 3.90 3.75 3.59 3.58
Celgene Corp. 12.12 12.03 11.25 11.77 10.72
Gilead Sciences Inc. 7.79 10.45 14.13 14.62 9.26
Johnson & Johnson 4.50 4.52 4.41 4.61 4.27
Merck & Co. Inc. 3.23 3.31 3.16 3.22 2.94
Pfizer Inc. 3.79 3.97 3.55 4.22 4.16
Regeneron Pharmaceuticals Inc. 2.49 2.33 2.57 2.89 3.99
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology 4.31 4.44 4.33 4.33 3.96
Net Fixed Asset Turnover, Industry
Health Care 7.11 7.33 7.00 6.93 6.50

Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

2017 Calculations

1 Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 22,871,300 ÷ 8,826,500 = 2.59

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017.

Total Asset Turnover

Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
Total assets 44,981,000  38,805,900  35,568,900  37,178,200  35,248,700 
Ratio
Total asset turnover1 0.51 0.55 0.56 0.53 0.66
Benchmarks
Total Asset Turnover, Competitors
Abbott Laboratories 0.36 0.40 0.49 0.49 0.51
AbbVie Inc. 0.40 0.39 0.43 0.72 0.64
Allergan PLC 0.13 0.11 0.11 0.25 0.38
Amgen Inc. 0.27 0.28 0.29 0.28 0.28
Biogen Inc. 0.52 0.50 0.55 0.68 0.58
Bristol-Myers Squibb Co. 0.62 0.58 0.52 0.47 0.42
Celgene Corp. 0.43 0.40 0.34 0.44 0.48
Gilead Sciences Inc. 0.37 0.53 0.62 0.71 0.48
Johnson & Johnson 0.49 0.51 0.53 0.57 0.54
Merck & Co. Inc. 0.46 0.42 0.39 0.43 0.42
Pfizer Inc. 0.31 0.31 0.29 0.29 0.30
Regeneron Pharmaceuticals Inc. 0.67 0.70 0.73 0.73 0.71
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology 0.37 0.38 0.38 0.44 0.43
Total Asset Turnover, Industry
Health Care 0.54 0.55 0.53 0.61 0.62

Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

2017 Calculations

1 Total asset turnover = Revenue ÷ Total assets
= 22,871,300 ÷ 44,981,000 = 0.51

Ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.

Equity Turnover

Eli Lilly & Co., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
Total Eli Lilly and Company shareholders' equity 11,592,200  14,007,700  14,571,300  15,373,200  17,631,400 
Ratio
Equity turnover1 1.97 1.52 1.37 1.28 1.31
Benchmarks
Equity Turnover, Competitors
Abbott Laboratories 0.89 1.02 0.96 0.94 0.87
AbbVie Inc. 5.54 5.53 5.79 11.46 4.18
Allergan PLC 0.22 0.19 0.20 0.46 0.91
Amgen Inc. 0.86 0.73 0.75 0.75 0.82
Biogen Inc. 0.97 0.94 1.15 0.90 0.80
Bristol-Myers Squibb Co. 1.77 1.20 1.16 1.07 1.08
Celgene Corp. 1.87 1.69 1.55 1.16 1.14
Gilead Sciences Inc. 1.26 1.59 1.73 1.59 0.95
Johnson & Johnson 1.27 1.02 0.98 1.07 0.96
Merck & Co. Inc. 1.17 0.99 0.88 0.87 0.88
Pfizer Inc. 0.74 0.89 0.75 0.70 0.68
Regeneron Pharmaceuticals Inc. 0.96 1.09 1.12 1.11 1.08
Equity Turnover, Sector
Pharmaceuticals & Biotechnology 0.98 0.93 0.88 0.96 0.93
Equity Turnover, Industry
Health Care 1.39 1.35 1.24 1.37 1.34

Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

2017 Calculations

1 Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders' equity
= 22,871,300 ÷ 11,592,200 = 1.97

Ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017.